Adcock Ingram: A picture of resilience in a challenging market

Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered…...

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here